AG
CBPO

Aperio Group’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Aperio Group’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-54
Closed -$5K – 3043
2019
Q2 		$5K Buy
+54
New +$5.09K ﹤0.01% 2868

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
YCMGA
York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Aperio Group's CBPO Position: Q3 2019 in Review

Aperio Group sold out of China Biologic Products Holdings, Inc. (CBPO) in Q3 2019, closing a stake of 54 shares — an estimated $5K sold.

Aperio Group first reported a position in CBPO in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 88 funds tracked by Wall St. Rank hold CBPO as of Q3 2019.

  • Aperio Group reported no remaining China Biologic Products Holdings, Inc. position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 54 China Biologic Products Holdings, Inc. shares in Q3 2019, an estimated $5K.
  • Aperio Group first reported a position in China Biologic Products Holdings, Inc. in Q2 2019 and held it in 1 quarter.
  • Aperio Group's China Biologic Products Holdings, Inc. position peaked at $5K in Q2 2019.
  • 88 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.